Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
作者： C. Pinto , F. Di Fabio , S. Siena , S. Cascinu , F.L. Rojas Llimpe
关键词:
摘要: Background: The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or …
annalsofoncology.org
oxfordjournals.org
oup.com
elsevier.com
paperity.org参考文章(31)
A Wakui, T Taguchi, Y Sakata, M Yoshino, Y Shimada, K Futatsuki, I Nakao, N Ogawa, M Kambe, [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 21, pp. 1033- 1038 ,(1994)
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
G Carpenter, S Cohen, Epidermal growth factor. Journal of Biological Chemistry. ,vol. 265, pp. 7709- 7712 ,(1972) , 10.1016/S0021-9258(19)38983-5
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Edmund A Gehan, None, The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent Journal of Chronic Diseases. ,vol. 13, pp. 346- 353 ,(1961) , 10.1016/0021-9681(61)90060-1
M Moehler, A Eimermacher, J Siebler, T Höhler, A Wein, M Menges, D Flieger, T Junginger, T Geer, E Gracien, P R Galle, M Heike, Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. British Journal of Cancer. ,vol. 92, pp. 2122- 2128 ,(2005) , 10.1038/SJ.BJC.6602649
C-H Köhne, R Catane, B Klein, M Ducreux, P Thuss-Patience, N Niederle, M Gips, P Preusser, A Knuth, M Clemens, R Bugat, I Figer, A Shani, B Fages, D Di Betta, C Jacques, H J Wilke, Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial British Journal of Cancer. ,vol. 89, pp. 997- 1001 ,(2003) , 10.1038/SJ.BJC.6601226
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74
Akira Tokunaga, Masahiko Onda, Takeshi Okuda, Tadashi Teramoto, Itsuo Fujita, Takashi Mizutani, Teruo Kiyama, Toshiro Yoshiyuki, Keigo Nishi, Norio Matsukura, Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbb-2 in human gastric cancer Cancer. ,vol. 75, pp. 1418- 1425 ,(1995) , 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y
Takuo Takehana, Kazuyoshi Kunitomo, Shioto Suzuki, Koji Kono, Hideki Fujii, Yoshiro Matsumoto, Akishi Ooi, Expression of epidermal growth factor receptor in gastric carcinomas Clinical Gastroenterology and Hepatology. ,vol. 1, pp. 438- 445 ,(2003) , 10.1016/S1542-3565(03)00219-2